NCT06935136View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma

NANot yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

October 9, 2026

Study Completion Date

April 9, 2028

Conditions
CAR-T Cell TherapyHigh-risk Large B-cell Lymphoma (LBCL)
Interventions
DRUG

Axicabtagene Ciloleucel

A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells

Trial Locations (1)

200025

China, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER

NCT06935136 - Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma | Biotech Hunter | Biotech Hunter